The PE Ratio as of November 2024 (TTM) for BeiGene, Ltd. (BGNE) is -23.23

According to BeiGene, Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -23.23. This represents a change of -19.01% compared to the average of -28.68 of the last 4 quarters.

BeiGene, Ltd. (BGNE) Historical PE Ratio (quarterly & annually)

How has BGNE PE Ratio performed in the past?

The mean historical PE Ratio of BeiGene, Ltd. over the last ten years is -24.11. The current -23.23 PE Ratio has changed 9.54% with respect to the historical average. Over the past ten years (40 quarters), BGNE's PE Ratio was at its highest in in the March 2021 quarter at 119.69. The PE Ratio was at its lowest in in the December 2014 quarter at -99.40.

BeiGene, Ltd. (BGNE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of BeiGene, Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BeiGene, Ltd. (BGNE) Average PE Ratio

How has BGNE PE Ratio performed in the past?

The current PE Ratio of BeiGene, Ltd. (BGNE) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

BeiGene, Ltd. (BGNE) PE Ratio vs. Peers

How is BGNE’s PE Ratio compared to its peers?

BeiGene, Ltd.’s PE Ratio is less than Ascendis Pharma A/S (-16.63), less than Apellis Pharmaceuticals, Inc. (-15.24), less than Akero Therapeutics, Inc. (-9.58), greater than Blueprint Medicines Corporation (-46.60), less than I-Mab (-1.73), less than Krystal Biotech, Inc. (104.40), less than Immunovant, Inc. (-12.18), less than Mirati Therapeutics, Inc. (-11.26), less than Incyte Corporation (425.32), less than BioMarin Pharmaceutical Inc. (37.97), less than ImmunoGen, Inc. (322.18), greater than Prometheus Biosciences, Inc. (-57.28), less than Arrowhead Pharmaceuticals, Inc. (-4.27), less than Ionis Pharmaceuticals, Inc. (-14.08), less than Legend Biotech Corporation (-21.42), less than Vaxcyte, Inc. (-21.57), less than Travere Therapeutics, Inc. (-4.04),

Build a custom stock screener for BeiGene, Ltd. (BGNE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeiGene, Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BeiGene, Ltd. (BGNE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BeiGene, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.